Pfizer Inc. Third Quarter Earnings on the Horizon

S&P 500 (NYSE:SPY) component Pfizer, Inc. (NYSE:PFE) will unveil its latest earnings on Tuesday, November 1, 2011. Pfizer is a global pharmaceutical company which develops and manufactures prescription medications for humans and animals.

Pfizer, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 56 cents per share, a rise of 3.7% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate moved down. It has risen from 55 cents during the last month. Analysts are projecting profit to rise by 0.9% versus last year to $2.25.

Past Earnings Performance: Last quarter, the company beat estimates by one cent, coming in at profit of 60 cents a share versus the estimate of net income of 59 cents a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Wall St. Revenue Expectations: On average, analysts predict $16.42 billion in revenue this quarter, a rise of 1.5% from the year ago quarter. Analysts are forecasting total revenue of $66.5 billion for the year, a decline of 1.9% from last year’s revenue of $67.79 billion.

Analyst Ratings: Analysts are bullish on this stock with 15 analysts rating it as a buy, none rating it as a sell and one rating it as a hold.

A Look Back: In the second quarter, profit rose 5.5% to $2.61 billion (33 cents a share) from $2.48 billion (31 cents a share) the year earlier, exceeding analyst expectations. Revenue fell 2% to $16.98 billion from $17.33 billion.

Key Stats:

The company has seen net income rise in three straight quarters. Net income rose 9.7% in the first quarter and more than threefold in the fourth quarter of the last fiscal year.

Revenue has fallen in the past two quarters. In the first quarter, the figure fell 1.5%.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Mylan Inc. (NASDAQ:MYL), Amgen, Inc. (NASDAQ:AMGN), and Sanofi-Aventis SA (NYSE:SNY).

Stock Price Performance: During September 28, 2011 to October 26, 2011, the stock price had risen $1.72 (9.8%) from $17.56 to $19.28. The stock price saw one of its best stretches over the last year between April 21, 2011 and May 2, 2011 when shares rose for seven-straight days, rising 6.2% (+$1.21) over that span. It saw one of its worst periods between July 6, 2011 and July 18, 2011 when shares fell for nine-straight days, falling 5.5% (-$1.13) over that span. Shares are up $2.31 (+13.6%) year to date.

(Source: Xignite Financials)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.